Remtolumab

DB15128Investigational

Remtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).

Mechanism: Pharmacologically active on Tumor necrosis factor and Interleukin-17A
Curator reviewed
Code names: ABT-122

Resolves to

Compound

UNII1V8WRH3RVXCAS1791410-27-9

Targets

P01375TNFQ16552IL17A

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Remtolumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account